The production and testing process behind each bottle — what gets checked, when, and by whom.
Every lot of Nerve Alive passes through a sequential quality program before release. Below is what each checkpoint involves and why it matters.
Production takes place in a U.S. facility holding FDA registration and operating under current Good Manufacturing Practice (cGMP) regulations as defined in 21 CFR Part 111. cGMP compliance requires documented procedures, equipment validation, personnel training records, and written master manufacturing records for every product — it is an auditable system, not a self-declaration.
Active ingredient potency is measured by High-Performance Liquid Chromatography (HPLC) against validated reference standards. This confirms that each capsule contains the doses printed on the label — not estimates based on supplier certificates alone. The method is validated for specificity, accuracy, linearity, and precision before being applied to a new lot.
Inductively Coupled Plasma Mass Spectrometry (ICP-MS) screens each lot for arsenic, cadmium, lead, and mercury at parts-per-billion sensitivity. Release thresholds are calibrated to California Proposition 65 limits — one of the most stringent heavy metal standards applied to dietary supplements in the U.S. market.
Per USP chapters 61 and 62, each lot is tested for total aerobic plate count, combined yeast and mold count, and for the absence of specific pathogens — Salmonella spp., E. coli, and Staphylococcus aureus. No lot is released without passing microbiological specifications.
Every bottle carries a stamped lot number that links to a single Certificate of Analysis for that production run. The COA records the specific test results — potency, heavy metals, microbiological counts — for that lot, not aggregate averages. This traceability allows specific lots to be identified and addressed if quality issues are discovered post-release.
The formula is produced without genetically modified ingredients, without gluten-containing components, and in vegetarian (non-gelatin) capsules. Allergen screening at the lot level is included in the release protocol. These attributes are verified rather than assumed from supplier documentation alone.